Converting enzyme inhibitor or AT1-receptor blocker for decreasing long-term mortality in patients, with stroke history and renal dysfunction?

被引：3

作者：

Fournier, A ^{[1
]}

Godefroy, O ^{[1
]}

Oprisiu, R ^{[1
]}

Slama, M ^{[1
]}

Andrejak, M ^{[1
]}

机构：

[1] CHU Hop Sud, Dept Nephrol, F-80054 Paris 1, France

来源：

STROKE | 2003年 / 34卷 / 01期

关键词：

D O I：

10.1161/01.STR.0000044950.15362.A4

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：8 / 9

页数：2

共 9 条

[1] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].

Brenner, BM ;

Cooper, ME ;

de Zeeuw, D ;

Keane, WF ;

Mitch, WE ;

Parving, HH ;

Remuzzi, G ;

Snapinn, SM ;

Zhang, ZX ;

Shahinfar, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869

[2] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].

Dahlöf, B ;

Devereux, RB ;

Kjeldsen, SE ;

Julius, S ;

Beevers, G ;

de Faire, U ;

Fyhrquist, F ;

Ibsen, H ;

Kristiansson, K ;

Lederballe-Pedersen, O ;

Lindholm, LH ;

Nieminen, MS ;

Omvik, P ;

Oparil, S ;

Wedel, H .

LANCET, 2002, 359 (9311) :995-1003

[3] Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:: the Captopril Prevention Project (CAPPP) randomised trial [J].

Hansson, L ;

Lindholm, LH ;

Niskanen, L ;

Lanke, J ;

Hedner, T ;

Niklason, A ;

Luomanmäki, K ;

Dahlöf, B ;

de Faire, U ;

Mörlin, C ;

Karlberg, BE ;

Wester, PO ;

Björck, JE .

LANCET, 1999, 353 (9153) :611-616

[4]

Holman Rury, 1998, BMJ, V317, P713

[5] Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].

Lewis, EJ ;

Hunsicker, LG ;

Clarke, WR ;

Berl, T ;

Pohl, MA ;

Lewis, JB ;

Ritz, E ;

Atkins, RC ;

Rohde, R ;

Raz, I .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860

[6]

LIU LS, 1995, CHINESE MED J-PEKING, V108, P710

[7] Does renal dysfunction predict mortality after acute stroke? A 7-year follow-up study [J].

MacWalter, RS ;

Wong, SYS ;

Wong, KYK ;

Stewart, G ;

Fraser, CG ;

Fraser, HW ;

Ersoy, Y ;

Ogston, SA ;

Chen, RL .

STROKE, 2002, 33 (06) :1630-1635

[8] Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial [J].

Mann, JFE ;

Gerstein, HC ;

Pogue, J ;

Bosch, J ;

Yusuf, S .

ANNALS OF INTERNAL MEDICINE, 2001, 134 (08) :629-636

[9]

PROGRESS Collaborat Grp, 2001, LANCET, V358, P1556, DOI 10.1016/S0140-6736(01)06178-5

← 1 →